Abstract
The development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatment advances, however, respiratory failure secondary to chronic bacterial pulmonary infection remains the primary cause of death in CF patients. The purpose of this review is to discuss emerging pathogens (other than Pseudomonas) in CF by describing the characteristics of the organism, their clinical significance in CF, their mechanisms of antimicrobial resistance and the current treatment approaches including newer pharmaceutical modalities. This review will focus on the following pathogens: Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, methicillin-resistant Staphylococcus aureus and nontuberculous mycobacteria The goal is to familiarize the reader with the challenges in treating pulmonary infections in CF caused by multi-drug resistant pathogens and to highlight some of the newer pharmaceutical treatments that are currently the focus of intense research.
Keywords: Cystic fibrosis, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter, respiratory pathogens, nontuberculous mycobacteria, multi-drug resistant pathogens, β-lactam drugs, chronic infection, biofilm formation
Current Pharmaceutical Design
Title: New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Volume: 18 Issue: 5
Author(s): Valerie Waters
Affiliation:
Keywords: Cystic fibrosis, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter, respiratory pathogens, nontuberculous mycobacteria, multi-drug resistant pathogens, β-lactam drugs, chronic infection, biofilm formation
Abstract: The development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatment advances, however, respiratory failure secondary to chronic bacterial pulmonary infection remains the primary cause of death in CF patients. The purpose of this review is to discuss emerging pathogens (other than Pseudomonas) in CF by describing the characteristics of the organism, their clinical significance in CF, their mechanisms of antimicrobial resistance and the current treatment approaches including newer pharmaceutical modalities. This review will focus on the following pathogens: Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, methicillin-resistant Staphylococcus aureus and nontuberculous mycobacteria The goal is to familiarize the reader with the challenges in treating pulmonary infections in CF caused by multi-drug resistant pathogens and to highlight some of the newer pharmaceutical treatments that are currently the focus of intense research.
Export Options
About this article
Cite this article as:
Waters Valerie, New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas, Current Pharmaceutical Design 2012; 18 (5) . https://dx.doi.org/10.2174/138161212799315939
DOI https://dx.doi.org/10.2174/138161212799315939 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brucella Pneumonia with Systemic Complications and Pancytopenia: A Case Report
Infectious Disorders - Drug Targets The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Candida parapsilosis Secreted Lipase as an Important Virulence Factor
Current Protein & Peptide Science Prediction of Degeneration of Native and Bioprosthetic Aortic Valves:Issue-Related Particularities of Diabetes Mellitus
Infectious Disorders - Drug Targets How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy The Oral Cavity, Biofilms and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Ruptured Multiple Mycotic Aneurysms Following Infective Endocarditis: Effectiveness of Catheter-based Techniques Using N-butyl Cyanoacrylate in a Hemorrhage-induced Coagulopathy
Current Medical Imaging Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology In Vitro Synergistic Action of Certain Combinations of Gentamicin and Essential Oils
Current Medicinal Chemistry Drug Delivery Systems Based on Titania Nanotubes and Active Agents for Enhanced Osseointegration of Bone Implants
Current Medicinal Chemistry Ceftriaxone-Vancomycin Drug Toxicity Reduction by VRP 1020 in Mus musculus Mice
Current Clinical Pharmacology Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry